$AII

Raymond James reiterates American Integrity Insurance stock rating on growth outlook

Raymond James reiterated an Outperform rating on American Integrity Insurance Group (AII) with a $27.00 price target. The stock, trading at $25.49, is considered undervalued with a Fair Value of $28.63. The firm expects high-single-digit policy growth through 2028, citing strong distribution relationships and favorable underwriting conditions. AII reported Q2 2026 adjusted earnings of $1.78 per share, beating estimates by 97.78%, with revenue of $115.17 million.

Original reporting
Published Oct 6, 2026, 10:07 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 6, 2026, 10:17 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefFinancial news
Primary signal
$AII
Bullish
medium confidence
Mentioned
$AII
Relevance
4/10
AlphAI data visualization · based on investing.com
Decision brief

The 30-second read

$AIIBullishLow
01

Why it matters

Analyst reiteration provides limited new trading impetus; price may inch higher.

02

Market read

Minor relevance; only the rating change adds new information.

03

What to watch

Potential catastrophe losses could offset upside.

Relevance 4/10Novelty 2/10Timing: none

Background

The article repeats Raymond James' rating and target for AII, referencing Q2 results that were released over a month earlier.

Company-level read

Ticker impact

$AIIBullishMedium confidence
Context

Raymond James reiterated an Outperform rating on AII and raised the price target to $27, citing growth outlook and recent Q2 earnings beat.

Expected impact

likely modest upside as investors price in the higher target

Evidence & confidence

The rating change is a fresh analyst action, but the underlying earnings were already public; impact is limited to sentiment.

Market effects

None significant; insurance sector unchanged.

No regional effect beyond AII.

Limited to AII investors.

Counterpoint

The upgrade may be premature if growth slows.

Key entities

  • Raymond James

    Equity research firm issuing the rating.

  • American Integrity Insurance Group

    US‑listed insurer (NYSE:AII).

Related articles

$AIIMedAI 8/10

American Integrity Insurance (AII) Q2 2026 Earnings Call Transcript

American Integrity Insurance (AII) reported Q2 2026 earnings with net income up 24.2% to $34.1M, diluted EPS up to $1.74, and gross premiums written up 13.8% to $326.6M. Policies in force grew 15.7% YoY to 461,714. The company expanded in the Tri-County region and middle-aged home segments, improved its combined ratio to 63.4%, and deployed $200M into fixed income securities.

$AIIMed

American Integrity Insurance Group Q2 Earnings Call Highlights

American Integrity Insurance Group (NYSE:AII) reported Q2 growth and underwriting results on an earnings call. Gross premiums written rose 13.8% to $326.6M and net premiums earned rose 58.2% to $104.7M. The combined ratio improved to 63.4% from 72.9%. Management reaffirmed annual catastrophe reinsurance costs of $430M to $440M and deployed nearly $200M into fixed-income securities.

$AIIMed

American Integrity Insurance Group, Inc. Reports Second Quarter 2026 Results

American Integrity Insurance Group, Inc. (AII) filed an SEC Form 8-K — Results of Operations and Financial Condition. American Integrity Insurance Group, Inc. Reports Second Quarter 2026 Results 43K voluntary new business policies sold in the quarter, a record for American Integrity, up 54% vs. the second quarter of 2025 and 44% vs. the first quarter of 2026 $46.4 million of income before income

$AZNHigh

A lung cancer trial found 21.1 months’ median survival with two drugs, versus 12.7 with one.

AstraZeneca's trial showed IMFINZI plus tarlatamab-dlle improved median survival to 21.1 months vs. 12.7 months with IMFINZI alone in extensive-stage small cell lung cancer. The combination reduced death risk by 58% and progression risk by 66%. Results were consistent across subgroups, including brain metastases. AstraZeneca aims to redefine treatment standards. Data presented at ESMO Congress 2026.

$AMGNHigh

IMDELLTRA® IN COMBINATION WITH IMFINZI® REDUCED RISK OF DEATH BY AN UNPRECEDENTED 58% IN FIRST-LINE EXTENSIVE STAGE SMALL CELL LUNG CANCER

Amgen (AMGN) announced that IMDELLTRA® combined with AstraZeneca's IMFINZI® reduced the risk of death by 58% in extensive stage small cell lung cancer (ES-SCLC) patients. Median overall survival increased to 21.1 months from 12.7 months with IMFINZI alone. The Phase 3 DeLLphi-305 study results were presented at ESMO Congress 2026 and published in The New England Journal of Medicine.